The efficacy of target specific therapies in lymphoma is limited to subgroups of patients. Scientists have identified a mechanism that confers resistance against a common therapy for lymphoma. They propose an alternative treatment that targets lymphoma signaling at its root, and show that it can be effective in a broader group of patients.